You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
国药指首针疫苗注射後十天可产抗体 疫苗保护期至少半年
阿思达克 01-15 12:31
国药集团中国生物董事长杨晓明表示,从国药集团中国生物新冠病毒灭活疫苗Ⅲ期临床试验的阶段性分析看,第一针注射10天後就可以产生抗体,但是,不同人之间抗体产生的差距很大,所以要打第二针。两针注射後,再过14天,就能产生高滴度抗体,形成有效保护,且全人群中和抗体阳转率达99%。

他指,正在密切观察疫苗保护期,目前最早接种疫苗的人已经做了8个多月的观察,结果显示依然有效。I期、II期临床受试者也在继续观察,从已经获得的数据看,半年没问题,能否保护8个月,正在测定,结果还没有出来。

他又指,国药集团中国生物分别在北京和武汉建成了新冠病毒灭活疫苗高等级生物安全生产车间,现已投入规模化生产,并正在进行整个新车间的模拟验证,通过後,2021年产能可达到10亿剂以上。三期产能,扩建将更大。

自去年7月22日正式启动新冠病毒疫苗的紧急使用以来,接种量不断增加,目前全国接种剂次已经超过1000万剂次。(ic/k) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account